Core Insights - Clearfield, Inc. reported a strong financial performance for fiscal year 2025, with net sales from continuing operations increasing by 20% to $150.1 million and gross profit margin improving significantly from 20.6% to 33.7% [3][10][11] - The company achieved a net income from continuing operations of $6.3 million, translating to earnings per share of $0.45, a substantial recovery from a net loss per share of $(0.58) in fiscal 2024 [4][12] - Clearfield anticipates continued growth in fiscal 2026, projecting revenue from continuing operations between $160 million and $170 million, and earnings per share in the range of $0.48 to $0.62 [3][13] Financial Performance - In Q4 2025, net sales from continuing operations reached $41.1 million, a 13% increase from $36.2 million in Q4 2024 [2][7] - Gross profit for Q4 2025 was $14.2 million, with a gross margin of 34.6%, up from 26.6% in the same quarter last year [2][8] - Operating expenses for Q4 2025 were $13.3 million, representing 32.3% of sales, a decrease from 33.4% in Q4 2024 [9][12] Strategic Developments - The company divested its European Nestor Cables business to focus on higher-return opportunities in North America, which aligns with its "Better Broadband and Beyond" strategy [5][6] - Clearfield's order backlog as of September 30, 2025, was $24.7 million, reflecting a decrease of 20% from the previous quarter but a 9% increase year-over-year [7] - The Board of Directors increased the share repurchase program authorization from $65 million to $85 million, indicating confidence in the company's market position [3][5] Outlook - For Q1 fiscal 2026, Clearfield expects net sales from continuing operations to be between $30 million and $33 million, with operating expenses remaining consistent with Q4 2025 [14] - The company does not foresee significant impacts from the results of discontinued operations on net income per share for the upcoming quarter [14] - Clearfield's management remains committed to disciplined growth and operational efficiency, despite potential pressures from external factors such as government funding delays [13][14]

Core Insights - Colliers has been named the World's Best Real Estate Adviser for the second consecutive year by Euromoney Global Real Estate Awards, reinforcing its status as a leading advisor in the industry [1][2] - The company received eight additional regional and national awards, highlighting its impact and performance in the commercial real estate market [2][4] Company Overview - Colliers operates as a global diversified professional services and investment management company, with three main platforms: Real Estate Services, Engineering, and Investment Management [3] - The company has a proven business model and an enterprising culture, delivering approximately 20% compound annual returns for shareholders over the past 30 years [3] - Colliers reported annual revenues of $5.5 billion and manages assets worth $108 billion, employing a team of 24,000 professionals [3]

Core Insights - ANI Pharmaceuticals, Inc. will have its CEO, Nikhil Lalwani, participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 [1] - The live and archived chat will be available on the company's website for 90 days [2] Company Overview - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics [3] - The company aims for sustainable growth through its Rare Disease business, Generics business, and Brands business, targeting areas such as ophthalmology, rheumatology, nephrology, neurology, and pulmonology [3]

Core Insights - Burlington Stores, Inc. reported a total sales increase of 7% in Q3 2025, with comparable store sales rising by 1% compared to Q3 2024 [2][4][5] - The company achieved a net income of $105 million, translating to diluted EPS of $1.63, which is an increase from $91 million or $1.40 per share in the same quarter last year [4][6] - Adjusted EPS grew by 16% to $1.80, and the company raised its full-year earnings guidance based on favorable margin and expense trends [2][4][10] Sales Performance - Total sales for Q3 2025 reached $2,706 million, up from $2,526 million in Q3 2024, while comparable store sales increased by 1% [4][5] - The gross margin rate improved to 44.2%, up from 43.9% in Q3 2024, reflecting a 30 basis point increase [5][6] Profitability Metrics - Adjusted EBIT margin increased by 60 basis points year-over-year, contributing to a strong earnings performance [2][4] - Adjusted EBITDA for Q3 2025 was $266 million, compared to $229 million in Q3 2024, marking an increase of 80 basis points as a percentage of sales [11] Inventory and Liquidity - Merchandise inventories rose by 15% to $1,658 million compared to $1,441 million at the end of Q3 2024, while comparable store inventories decreased by 2% [8] - The company ended Q3 2025 with $1,532 million in liquidity, including $584 million in unrestricted cash [12] Share Repurchase and Debt Management - During Q3 2025, Burlington repurchased 213,972 shares for $61 million, with $444 million remaining under its share repurchase program [9] - Total outstanding debt was $2,035 million, with $1,723 million on its Term Loan facility [12] Future Outlook - For the full fiscal year 2025, the company expects total sales to increase by approximately 8% and comparable store sales to rise between 1% to 2% [10][20] - The company plans to open 104 net new stores and anticipates capital expenditures of approximately $950 million [13][20]

Core Insights - Titan Machinery Inc. achieved a cumulative inventory reduction of $98 million in the first nine months of fiscal 2026 and has increased its inventory reduction target for the full year to $150 million from a previous target of over $100 million [1][2][3] - The company reported a revenue of $644.5 million for the third quarter of fiscal 2026, a decrease from $679.8 million in the same quarter last year [3][36] - Equipment revenue for the third quarter was $459.9 million, down from $495.1 million year-over-year, while parts revenue slightly increased to $122.3 million from $121.1 million [3][36] Financial Performance - Gross profit for the third quarter was $111.0 million, with a gross profit margin of 17.2%, compared to $110.5 million and 16.3% in the same quarter last year [4][36] - Operating expenses rose to $100.5 million, up from $98.8 million year-over-year, resulting in an operating expense as a percentage of revenue of 15.6% compared to 14.5% [5][36] - Net income for the third quarter was $1.2 million, with diluted earnings per share of $0.05, compared to net income of $1.7 million and earnings per share of $0.07 in the prior year [7][36] Segment Analysis - The Agriculture segment reported revenue of $420.9 million, down 12.3% year-over-year, attributed to lower demand driven by reduced commodity prices and high interest rates [8][10] - The Construction segment's revenue decreased to $76.7 million, reflecting a 10.1% decline, primarily due to lower equipment sales [10][36] - The Europe segment saw significant growth, with revenue increasing to $117.0 million from $62.4 million, largely due to EU stimulus programs, resulting in a pre-tax income of $3.5 million compared to a loss in the previous year [11][36] Inventory and Cash Flow - Total inventories decreased by $97.9 million to $1.0 billion as of the end of the third quarter, with equipment inventories down by $96.9 million [13][36] - The company reported net cash provided by operating activities of $83.9 million for the nine months ended October 31, 2025, compared to a net cash used of $56.2 million in the same period last year [14][36] Management Commentary - The CEO highlighted the stronger-than-expected equipment margins and the ongoing inventory optimization efforts, while also noting the anticipated recognition of a non-cash valuation allowance that may increase tax expenses in the fourth quarter [15][36] - The company remains focused on improving performance and positioning itself for better market conditions in fiscal 2027 [15][36] Modeling Assumptions - Updated modeling assumptions for fiscal 2026 indicate that agriculture revenue is expected to decline by 15% to 20%, construction revenue by 5% to 10%, while Europe revenue is projected to increase by 35% to 40% [16][36]

Core Viewpoint - Nokia Corporation has announced its delisting from the Euronext Paris stock exchange, with the delisting expected to take effect on December 31, 2025, following approval from the Board of Euronext Paris [1][3]. Summary by Sections Delisting Announcement - The decision to delist was made after a review of trading volumes, costs, and administrative requirements associated with the listing on Euronext Paris, which was initially established in April 2015 during the acquisition of Alcatel-Lucent [2]. Impact on Operations - The delisting will not affect Nokia's daily operations in France or its listings on Nasdaq Helsinki and the New York Stock Exchange, where shares are traded as American Depositary Receipts [3]. Voluntary Sales Facility - A voluntary sales facility will be established to allow shareholders to sell their Nokia shares listed on Euronext Paris. Shareholders can trade until December 30, 2025, the last trading day before the delisting [4][9]. - Shareholders wishing to sell their shares through this facility must instruct their financial intermediaries to deliver shares to Société Générale between December 2, 2025, and December 15, 2025 [5]. Sale Process - Shares delivered to Société Générale will be sold on Nasdaq Helsinki starting January 2, 2026, at the prevailing market price. Nokia will not be involved in the sale process, which will be managed independently by Société Générale [6][8]. - Société Générale will calculate the average sale price during the sales period and transfer the proceeds to shareholders once received [7]. Indicative Calendar - Key dates related to the voluntary sales facility and delisting include: - Euronext notice regarding the Sales Facility: November 27, 2025 - Beginning of the voluntary Sales Facility period: December 2, 2025 - End of the voluntary Sales Facility period: December 15, 2025 - Last day of trading on Euronext Paris: December 30, 2025 - Delisting from Euronext Paris: December 31, 2025 - Sale on Nasdaq Helsinki: Beginning January 2, 2026 [11].

HOUSTON and LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- LyondellBasell (NYSE: LYB), a leader in the global chemical industry, today announced Agustin Izquierdo, executive vice president and chief financial officer, will participate in a fireside chat at the 2025 Goldman Sachs Industrials and Materials Conference in New York on Wednesday, December 3, 2025, at 9:20 a.m. EST. Webcast and Presentation Slides AccessA live webcast can be accessed at the time of the event at https://investors.lyondellbasell.com/eve ...

Core Insights - The company reported a decrease in revenue for the fourth quarter and the full fiscal year 2025, primarily due to advanced distributor ordering and ongoing business dynamics in China [2][10][11] - Despite the revenue decline, the company achieved higher profitability metrics, including increased GAAP operating margin and net income year over year [3][10] - The company completed the first phase of its strategic roadmap and initiated the second phase focused on growth, operational efficiency, and debt reduction [3][9] Fourth Quarter Fiscal Year 2025 Financial Highlights - Reported revenues were $264.0 million, down 7.7% from $286.1 million in the prior year [6][10] - U.S. revenues decreased by 15.2%, while international revenues increased by 2.8% on a reported basis [6][8] - Gross profit was $158.5 million with a margin of 60.0%, compared to $173.8 million and 60.7% in the prior year [6][19] - Net income was $26.4 million, with diluted earnings per share of $0.45, compared to $14.6 million and $0.25 in the prior year [6][19] Twelve Months Ended September 30 Fiscal Year 2025 Financial Highlights - Reported revenues totaled $1,080.4 million, down 3.8% from $1,123.1 million in the previous year [11][19] - U.S. revenues decreased by 4.6%, while international revenues decreased by 2.8% on a reported basis [11][19] - Gross profit was $676.8 million with a margin of 62.6%, compared to $735.2 million and 65.5% in the prior year [11][19] - Net income was $95.4 million, with diluted earnings per share of $1.62, compared to $78.3 million and $1.34 in the prior year [11][19] Strategic Initiatives and Future Outlook - The company aims to strengthen its core business and expand its product portfolio, particularly in the GLP-1 strategy [9][12] - Fiscal year 2026 guidance anticipates reported revenues between $1,071 million and $1,093 million, with an expected revenue growth of -0.9% to 1.1% [12][13] - The company plans to maintain a strong adjusted operating margin of 29.0% to 30.0% in fiscal year 2026 [12][13] Balance Sheet and Liquidity - As of September 30, 2025, the company had $228.6 million in cash and equivalents and $1.417 billion in debt principal outstanding [15][19] - The company repaid approximately $72.4 million of outstanding principal under its term loan B facility during the fourth quarter [9][15] - A quarterly cash dividend of $0.15 per share was declared, payable on December 18, 2025 [16]

Core Insights - Novo Nordisk announced positive results from a phase 2 clinical trial of amycretin for type 2 diabetes, highlighting its commitment to innovation in diabetes treatment [1][8][9] Trial Overview - The trial involved 448 participants with type 2 diabetes inadequately controlled on metformin, with or without SGLT2 inhibitors, and assessed the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous and once-daily oral amycretin [2][12] - The study included multiple ascending doses, with six subcutaneous doses ranging from 0.4 mg to 40 mg and three oral doses of 6 mg, 25 mg, and 50 mg, over a treatment duration of up to 36 weeks [2][12] Efficacy Results - Subcutaneous amycretin achieved a maximum HbA1c reduction of -1.8% from a baseline of 7.8%, with 89.1% of participants reaching HbA1c <7% and 76.2% achieving ≤6.5% [3][11] - Oral amycretin resulted in a maximum HbA1c reduction of -1.5% from a baseline of 8.0%, with 77.6% achieving HbA1c <7% and 62.6% achieving ≤6.5% [4][11] - Placebo groups showed minimal improvements in HbA1c, confirming the statistical significance of amycretin's efficacy [5] Weight Loss Outcomes - Subcutaneous amycretin led to a statistically significant weight loss of up to -14.5% from a baseline weight of 99.2 kg, compared to -2.6% in the placebo group [6][11] - Oral amycretin resulted in a weight loss of up to -10.1% from a baseline weight of 101.1 kg, also significantly better than the placebo [6][11] Safety Profile - Both subcutaneous and oral amycretin demonstrated a safe and well-tolerated profile, with gastrointestinal issues being the most common adverse events, primarily mild to moderate in severity [7][11] Future Development Plans - Based on the positive phase 2 results, Novo Nordisk plans to initiate a phase 3 development program for amycretin targeting adults with type 2 diabetes in 2026 [9][10]

Group 1 - The company PARKEN Sport & Entertainment A/S announced a share buyback program totaling 30 million DKK, with a maximum of 400,000 shares at a nominal value of 20.00 DKK each, to be executed from February 4, 2025, until December 31, 2025 [1] - The buyback program is conducted in accordance with EU regulations, specifically Article 5 of Regulation (EU) No. 596/2014 and Chapter II of Delegated Regulation (EU) 2016/1052, known as "Safe Harbour rules" [2] - As of week 47, a total of 7,984 shares have been repurchased under the buyback program, representing 0.08085% of the company's share capital, in addition to an existing holding of 105,689 shares, which accounts for 1.07025% of the share capital [2]